PUBLIC RELEASE DATE: <\/p>\n
3-Jun-2014 <\/p>\n
Contact: Lester Kok lesterkok@ntu.edu.sg<\/a> 65-679-06804 Nanyang Technological University<\/p>\n Scientists from Nanyang Technological University (NTU) and the Singapore Eye Research Institute (SERI) have jointly developed a new nanomedicine that will allow glaucoma patients to do away with daily eye drops. <\/p>\n Glaucoma is a disease which could lead to blindness. This new sustained-release drug therapy can provide months of relief to glaucoma patients with a single application, compared to just hours with today's conventional eye drops. <\/p>\n The new therapy has successfully gone through a pilot study with six patients conducted at the Singapore National Eye Centre and has yielded exceptional results, having shown to be both safe and effective in the treatment of glaucoma. <\/p>\n A leading cause of blindness in the world especially for the elderly, glaucoma is caused by high intra-ocular pressure in the eye which then leads to damage to the optic nerve. Conventionally, the first line of treatment for glaucoma patients is the daily application of eye drops which can lower the high pressure in their eyes. This treatment is usually required for the rest of the patients' lives as glaucoma is a chronic disease. <\/p>\n Co-lead scientist Associate Professor Tina Wong, who is the head of the Ocular Therapeutics and Drug Delivery Research Group at the Singapore Eye Research Institute, said the new nanomedicine will benefit the elderly, as they often forget to use the daily eye drops, leading to the worsening of their conditions. <\/p>\n \"It is estimated that at least ten per cent of blindness from glaucoma is directly caused by poor patient adherence to their prescribed medications,\" says Dr Wong, an Adjunct Associate Professor with NTU's School of Materials Science and Engineering. <\/p>\n \"Many patients find it difficult to adhere to their doctor's prescribed regime for many reasons, such as forgetfulness, finding it too troublesome, or they lack understanding of the disease. The results in this clinical study will open up a new treatment modality for glaucoma other than taking daily eye drops, and will greatly enhance patient compliance and improve treatment outcomes,\" she said. <\/p>\n <\/p>\n Read this article: PUBLIC RELEASE DATE: 3-Jun-2014 Contact: Lester Kok lesterkok@ntu.edu.sg<\/a> 65-679-06804 Nanyang Technological University Scientists from Nanyang Technological University (NTU) and the Singapore Eye Research Institute (SERI) have jointly developed a new nanomedicine that will allow glaucoma patients to do away with daily eye drops. Glaucoma is a disease which could lead to blindness Continue reading
\nNew nanomedicine by NTU and SERI scientists to bring relief to glaucoma patients<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"